Cynata’s Preclinical Study Demonstrates Anti-Cancer Effects From Engineered Cymerus MSCs

Clinical stage Biotechnology company Cynata Therapeutics Limited (ASX:CYP) announced the results of preclinical studies in the development of genetically engineered cell produced using the Cymerus platform to treat various cancer.

Professor Khalid Shah, the one directed the conducted of study, stated that the study results suggest the use of engineered Cymerus MSCs for cell therapy to aim various tumors treatment. He said that the results of this preclinical program have proven the use of cell-based approach for cancer treatment, as it provides a persistent pool of therapeutic protein around the tumor cells, circumventing the protein short half-lives.

The company told that engineered Cymerus cells, derived from mesenchymal stem cells (MSCs), have been successfully produced to express diagnostic and therapeutic anti-cancer agents. Also, it can be tracked by real time imaging in ‘vivo’ to facilitate a statistically significant therapeutic effect in a preclinical mouse model of glioblastoma, i.e. brain cancer. Subsequently the study outcome revealed that Engineered Cymerus cells have presented the highly promising therapeutic advantages in various mouse tumor models.Â

As per the preliminary study outcome, the proprietary Cymerus platform technology of Cynata Therapeutics has proven to be successfully engineered to express genes from other cells in a stable manner.

The first stage of the preclinical program was aimed to evaluate the viability of a lentiviral engineering process use to cause Cymerus mesenchymal stem cells (MSCs) express transgenes and to check the persistence of engineered cells in mouse models. Under this study, the researchers have also evaluated the anti-cancer effects of engineered Cymerus MSCs on the feasibility of both human skin cancer and human brain cancer through vitro test.

Whereas, in the second stage of the study the engineered Cymerus MSCs have shown to cast a reduction in the feasibility of human glioblastoma (brain cancer) cells and in melanoma (skin cancer) cells, in comparison to control or the direct administration of the therapeutic protein. Further, the results revealed that in a vivo mouse model of brain cancer, tumor advancement in mice that received the engineered Cymerus MSCs was at slow pace compared to the ones receiving the control.

Cynata’s Vice President, Product Development Dr Kilian Kelly stated that the highly encouraging results obtained from preclinical study indicates the potential of Cymerus platform to be exploited to generate targeted anti-cancer therapies. He added this will create significant benefits over traditional cancer treatments, from both efficacy and safety perspective.

Recently in September, the company has demonstrated the Cymerus MSCs potential in reducing the effects of Cytokine release syndrome (CRS) in murine model. The study has shown that Cymerus MSCs can effectively treat the CRS syndrome along with improving body temperature.

With the release of preclinical study outcome, Cynata’s stock plunged 4% to last trade at $1.200 on 19 October 2018. The stock has seen a performance change of +86.57% over the past one year but it is drifting lower since past recent months. It has gone as much as 4.58% down over last three months.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.

Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.